Literature DB >> 17918289

The impact of treatment interruptions on locoregional control during postoperative breast irradiation.

N S Bese1, P A Sut, N Sut, A Ober.   

Abstract

PURPOSE: Patients treated in the years 1990-2003 with breast conserving surgery and postoperative adjuvant radiotherapy were retrospectively analyzed in order to determine the impact of radiotherapy interruptions on the treatment outcome. PATIENTS AND METHODS: 470 patients received breast irradiation with (60)Co or with 4MV photon linear accelerator (total dose 50 Gy, range 46-54). Four hundred and sixty-two (98%) patients had boost dose of 10-20 Gy to the tumor bed either with photon or electron irradiation. Irradiation of the lymphatic fields was carried out according to the number of involved nodes. Even one day of treatment break was accepted as treatment interruption. Unplanned treatment interruptions occurred in 423 (90%) patients. A total of 196 (41%) patients had no treatment breaks or had interruptions of 7 days or less and 274 (59%) patients had treatment interruptions longer than 7 days. Locoregional control (LC) and overall survival (OS) rates were estimated by Kaplan-Meier method. The groups were compared with log-rank x(2) and Pearson x(2) tests.
RESULTS: For all patients 5-year LC and OS rates were 91% and 85%, and 10-year rates were 86% and 75%, respectively. LC rates for the group of patients without interruptions or with an interruption of less than a week were 95% for 5 years and 90% for 10 years. Five- and 10-year LC rates for the patients with interruptions of 8 days or more were 87% and 83%, respectively (p=0.02).
CONCLUSION: This retrospective study shows that postoperative irradiation interruptions of more than a week negatively impact LC.

Entities:  

Mesh:

Year:  2007        PMID: 17918289

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  7 in total

1.  Radiotherapy treatment interruptions during the Covid-19 pandemic: The UK experience and implications for radiobiology training.

Authors:  R G Dale; B Jones
Journal:  Radiat Phys Chem Oxf Engl 1993       Date:  2022-05-06       Impact factor: 2.776

2.  Significant suppression of radiation dermatitis in breast cancer patients using a topically applied adrenergic vasoconstrictor.

Authors:  James F Cleary; Bethany M Anderson; Jens C Eickhoff; Deepak Khuntia; William E Fahl
Journal:  Radiat Oncol       Date:  2017-12-22       Impact factor: 3.481

3.  Association between cumulative radiation dose, adverse skin reactions, and changes in surface hemoglobin among women undergoing breast conserving therapy.

Authors:  Michael S Chin; Leah Siegel-Reamer; Gordon A FitzGerald; Allison Wyman; Nikole M Connor; Yuan-Chyuan Lo; Shirin Sioshansi; Janaki Moni; Maria Giulia Cicchetti; Janice F Lalikos; Thomas J FitzGerald
Journal:  Clin Transl Radiat Oncol       Date:  2017-05-18

4.  Predictors for Fear of Cancer Recurrence in Breast Cancer Patients Referred to Radiation Therapy During the COVID-19 Pandemic: A Multi-Center Cross-Section Survey.

Authors:  Jinrong Xie; Weixiang Qi; Lu Cao; Yuting Tan; Jin Huang; Xiaodong Gu; Bingguang Chen; Peipei Shen; Yutian Zhao; Ying Zhang; Qingwen Zhao; Hecheng Huang; Yubin Wang; Haicheng Fang; Zhenjun Jin; Hui Li; Xuehong Zhao; Xiaofang Qian; Feifei Xu; Dan Ou; Shubei Wang; Cheng Xu; Min Li; Zefei Jiang; Yu Wang; Xiaobo Huang; Jiayi Chen
Journal:  Front Oncol       Date:  2021-07-26       Impact factor: 6.244

5.  Assessment of Breast Cancer Management in Sub-Saharan Africa.

Authors:  Verna Vanderpuye; Mary-Ann Dadzie; Dezheng Huo; Olufumilayo I Olopade
Journal:  JCO Glob Oncol       Date:  2021-09

6.  Quantitative evaluation of radiodermatitis following whole-breast radiotherapy with various color space models: A feasibility study.

Authors:  So-Yeon Park; Jin Ho Kim; Ji Hyun Chang; Jong Min Park; Chang Heon Choi; Jung-In Kim
Journal:  PLoS One       Date:  2022-03-09       Impact factor: 3.240

7.  Hyperspectral Imaging as an Early Biomarker for Radiation Exposure and Microcirculatory Damage.

Authors:  Michael S Chin; Brian B Freniere; Luca Lancerotto; Jorge Lujan-Hernandez; Jonathan H Saleeby; Yuan-Chyuan Lo; Dennis P Orgill; Janice F Lalikos; Thomas J Fitzgerald
Journal:  Front Oncol       Date:  2015-10-26       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.